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This research project addressed 2 related questions: 
The first question relates to prevalence of the 6 known aminoglycoside-induced deafness 
mutations in the MT-RNR1 gene in a cohort of MDR-TB patients. This data has been 
published and has been cited in sections where referred to in the text. This data has been 
included as it forms part of the genetics arm of the study.  
   
This dissertation addresses the second question which relates to the incidence of 
aminoglycoside–induced hearing loss in a cohort of patients with MDR–TB. The results of 
this study showed that HIV positive patients on antiretroviral drugs were more likely to 
develop hearing loss than HIV negative patients. Guidelines for the medical fraternity on 
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Aminoglycosides are clinically important drugs that are used in the treatment of aerobic 
gram-negative bacterial infections and chronic infections such as tuberculosis (TB) caused by 
resistant mycobacteria strains.1 The ototoxic effects of aminoglycoside antibiotics are well 
documented. 
Aminoglycoside drugs exert their antibacterial effects by binding to the 16S rRNA in the 30S 
subunit of the bacterial ribosome and cause mistranslation or premature termination of 
protein synthesis.2,3 The following mechanism for aminoglycoside ototoxicity in humans has 
been proposed: the aminoglycosides bind to the mitochondrial 12S rRNA, which shares 
structural similarity with its bacterial counterpart.2,3  This binding inhibits mitochondrial 
protein synthesis causing a decline in adenosine triphosphate (ATP) production. This in turn, 
leads to an increase in the levels of toxic reactive oxygen species (a by-product of 
respiration), causing damage to mitochondrial and cellular proteins, lipids and nucleic acids.2 
This results in apoptosis of the cochlear outer hair cells and receptor cells of the vestibular 
organ, leading to hearing and vestibular impairment.2  
Aminoglycosides can damage the cochlea in a dose-dependent fashion, but there are also 
patients who have a genetic predisposition to aminoglycoside ototoxicity due to mutations in 
the mitochondrial 12S rRNA, who may suffer an idiosyncratic reaction (after a single dose).4 
There are six known mutations in the MT-RNR1 gene which predispose patients to 
aminoglycoside ototoxicity: A1555G, C1494T, T1095C, 961delT+C(n), A827G and T1291C. 
All 12S rRNA molecules harbouring the A1555G or C1494T mutations (and possibly the 
T1095C and the 961 delT+ C mutations), either take up a secondary structure that more 
closely resembles the bacterial 16S rRNA, or creates a new binding site that results in greater 
aminoglycoside binding.5 ,6,7,8  
Due to its low cost and efficacy, aminoglycosides remain widely used in developing countries 
and therefore aminoglycoside ototoxicity remains a major problem. Depending on the 
population studied, aminoglycoside ototoxicity accounts for 3 to 30% of hearing loss.9   This 
high prevalence rate may be attributed to genetic susceptibility from mitochondrial mutations 
in the 12S rRNA gene, the unregulated use of aminoglycoside antibiotics,  or other 
predisposing factors.9 Risk factors like advanced age , renal dysfunction and concomitant 
ototoxins are well documented .4 
The literature suggests that mitochondrial mutations in the 12S rRNA are rare (between 
0.09% and 3.96%), depending on the population studied.10, 11  Due to the rarity of these 












excessive risk of ototoxicity often seen in developing countries. There may be other 
environmental factors that cause patients to be at increased risk. 
The incidence of TB is highest amongst patients with advanced human immunodeficiency 
virus (HIV) infection.12 Patients with advanced HIV are treated with highly active 
antiretroviral therapy (HAART). In HAART, a combination of antiretroviral drugs is used to 
suppress viral replication. The recommended drug combination for patients who have not yet 
been treated for HIV consists of two nucleoside  reverse transcriptase inhibitors (NRTIs), 
together with a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor 
(PI). Individually these drugs have a range of significant toxicities.13 
Prior cross-sectional studies and case reports have shown an association between hearing loss 
and nucleoside reverse transcriptase inhibitors (NRTIs).14, 15, 16 The mechanism by which 
NRTIs cause auditory dysfunction includes damage to the mitochondrial DNA.17 
Mitochondrial anomalies have been linked to a number of causes of hearing loss namely, 
presbyacusis 18, non-syndromic hearing loss19, and of course genetic susceptibility to 
aminoglycoside-induced hearing loss. Since NRTIs cause mitochondrial dysfunction, patients 
who are taking NRTIs may theoretically be more at risk of hearing loss when exposed to 
aminoglycosides.  If this were to be the case, then a significant number of people are 
potentially at increased risk of aminoglycoside ototoxicity from concomitant antiretroviral 
administration; far more so than those from genetic susceptibility. 
Brooklyn Chest Hospital in Cape Town, is a dedicated TB hospital where patients with 
tuberculosis are hospitalised for periods of between 2 to 4 months and receive systemic 
streptomycin (for retreatment tuberculosis), or kanamycin (for multidrug resistant 
tuberculosis). Anecdotal evidence suggests that a significant proportion of the patients 
experience mild to profound hearing loss. It would be important to establish how many of 
these patients harbour a genetic mutation which would predispose them to aminoglycoside-
induced ototoxicity. It would also be important to identify individuals who are at risk of 
irreversible hearing loss if treated with aminoglycoside antibiotics and to counsel them 
accordingly. 
As part of hospital protocol, all patients are routinely tested for HIV (once consented), unless 
the HIV status is already known. Pre- and post-test counselling is done by the hospital HIV 
















 The incidence of aminoglycoside-induced hearing loss is high in the local TB 
population. 
 HIV positive patients are at increased risk of aminoglycoside ototoxicity. 
 
Aims of the study 
 To document the incidence and severity of aminoglycoside-induced ototoxicity at 
Brooklyn Chest Hospital. 
 To determine the prevalence of the 6 known aminoglycoside-induced deafness 
mutations in the MT-RNR1 gene (A1555G, C1494T, T1095C, T1291C, A827G and 
961 indel C) in a cohort of MDR-TB patients.* 
 To determine whether HIV positive MDR-TB patients are more likely to develop 
aminoglycoside-induced hearing loss than HIV negative MDR-TB patients. 
 To provide clinical guidelines to the medical fraternity on the use of aminoglycoside 
antibiotics with regard to the side-effect of ototoxicity. 
 
Inclusion Criteria 
 Patients with multidrug-resistant pulmonary tuberculosis who received streptomycin, 
kanamycin, or amikacin. 
 Aminoglycoside treatment started on admission or within three months prior to 
admission to hospital. 
 HIV positive patients on antiretroviral treatment and HIV negative patients. 
 Patients with normal hearing on admission (defined as pure tone average < 25dB). 
 
Exclusion Criteria 
 Patients with sensorineural hearing loss (defined as pure tone average > 25dB). 
 Patients with conductive hearing loss. 
 Patients who started aminoglycoside treatment >3 months before admission. (Patients 
are often started on aminoglycosides in the community). 
 Patients with renal dysfunction. 
 
Material and Method 












 Study participants were recruited from Brooklyn Chest Hospital, Cape Town. 
 Study was approved by the University of Stellenbosch’s Committee for Human 
Research (study approval number N05/09/165), as well as the University of Cape 
Town’s Research Ethics Committee (study approval number 443/2005).  
 Informed written consent was obtained from each individual participating in this 
study and in the case of minors consent was obtained from their legal guardians. 
 
Genetics Testing* 
 Peripheral blood samples were collected in EDTA-coated tubes from each study 
participant and genetic testing performed to screen for the six known aminoglycoside-
induced deafness mutations in the MT-RNR1 gene (A1555G, C1494T, A827G, 
T1291C, T1095C and 961 indelC) using the new SNAPshot technique developed by 
the Tygerberg Genetics Department.*20, 21 
 Polymerase chain reaction (PCR) primers and SnapShot primers were specially 
designed that spanned the entire length of the MT-RNR1 gene.20 
 The SnapShot technique can detect the 6 known mutations in a single reaction.20 
 
As part of the hospital’s protocol 
 Blood was tested for urea and electrolytes routinely at least once monthly and if 
deranged, aminoglycosides were stopped and treatment altered. 
 Informed consent was obtained from patients for HIV testing (done routinely where 
HIV status was unknown). 
 Pre- and post-test counselling done by the hospital HIV counsellor. 
 
Data collection included 
1. Age 
2. Gender 
3. Ethnic group  
4. Specific  aminoglycoside therapy 
5. Recent exposure to aminoglycoside (within the last 6 months) 
6. History of noise exposure 
7. Presence of tinnitus 












Audiology Protocol  
 All the audiology tests were undertaken in a sound-treated booth in the audiology 
department at Brooklyn Chest Hospital. 
 Otoscopy, tympanometry, conventional pure tone audiometry were done on admission 
as a baseline evaluation, and then at weeks 4, 8 and 12. 
 A study period of three months was elected as this was the average length of 
hospitalisation for patients. 
 
Otoscopy 
 Heine Minilux otoscope was used for non-diagnostic otoscopic examinations by 
the audiologist. 
 Non-diagnostic otoscopy involved visual inspection of the external auditory 
meatus and tympanic membrane. If any abnormalities of these structures were 
observed, appropriate referral was made after the participant’s consent to do so. 
 
Tympanometry 
 Portable tympanometer was used for tympanometry. 
 If abnormalities were detected on tympanometry, appropriate referral was made 
and the individual excluded from the study. 
 
Conventional Audiometry 
 Amplaid 308 audiometer and TDH-39 headphones were used for conventional 
audiometry. 
 Before commencing the test protocol, all tests were explained to the participant in 
the appropriate language. 
 Clear instructions were given before each procedure, and repeated during the test 
if necessary. 
 Pure tone air conduction testing using pure tones from 250 to 8000 Hz at octave 
intervals was performed. 
 Pure tone audiogram testing started at 0 dB HL at 1000 Hz, using an ascending 
approach. 
 The participants had to raise a hand to indicate when the tone was detected.  












Severity of hearing loss was graded as: 
 0-25 dB HL                                        Within normal limits 
 26-40 dB HL                                       Mild    
 41-55 dB HL                                       Moderate 
 56-70 dB HL                                       Moderate to Severe (or moderately severe) 
 71-90 dB HL                                       Severe 
 91+   dB HL                                        Profound                                          
 
Analysis of results 
 Incidence of aminoglycoside-induced ototoxicity in a cohort of MDR-TB patients. 
 Severity of hearing loss. 
 Prevalence of known aminoglycoside-induced deafness mutations in the MT-RNR1 
gene [A1555G, C1494T, T1095C, T1291C, A827G, 961delT+C(n)] in a cohort of 
MDR-TB patients who develop ototoxicity.*21 
 Incidence of hearing loss in HIV positive MDR-TB patients on HAART. 
 
Possible Conclusions 
 The incidence of aminoglycoside-induced ototoxicity in MDR-TB patients is high. 
 Genetic predisposition to aminoglycoside-induced hearing loss does not play a major 
role in our population. 


























1. Forge A., Schacht, J., 2000. Aminoglycoside antibiotics. Audiology and Neurootology, 
5(1), pp.3-22. 
2. Matsui J.I., Gale J.E., Warchol, M.E. 2004. Critical signalling events during the 
aminoglycoside induced death of sensory hair cells in vitro. Journal of Neurobiology, 
61(2), pp.250-266. 
3. Forge A., Li, L., 2000. Apoptic death of hair cells in mammalian vestibular sensory 
epithelia. Hearing Research, 139(1-2), pp.97-115. 
4. Moore R.D., Smith, C.R., Lietman, P.S., 1984. Risk factor for the development of 
auditory toxicity in patients receiving aminoglycosides. Journal of Infectious Diseases, 
149(1), pp.23-30. 
5. Qian Y., Guan M.X., 2009. Inteaction of aminoglycoside with Human Mitochondrial 12S 
rRNA carrying the Deafness- Associated Mutation. Antimicrobial Agents and 
Chemotherapy, 53(11), pp.4612-4618. 
6. Prezant, T.R., Agapian, J.V., Bohlman, M.C., Bu, X., Oztaz, S., et al., 1993. 
Mitochondrial ribosomal RNA mutation associated with both antibiotic induced and non 
syndromic deafness. Nature Genetics, 4(3), pp.289-294.  
7. Bacino, C., Prezant, T.R., Bu, X., Fournier, P., Fisch-Ghodsian, N., 1995. Susceptibility 
mutations in the mitochondrial small ribosomal RNA gene in aminglycoside induced 
deafness. Pharmacogenetics, 5(3), pp.165-172. 
8. Zhao, H., Li, R., Wang, Q., Yan, Q., Deng, J.H., 2004. Maternally inherited 
aminoglycoside –induced and non-syndromic deafness is associated with the novel 
C1494T mutation in the mitochondrial 12sRNA gene in a large Chinese family. American 
Journal of Human Genetics, 74(1), pp.139-152. 
9. Saunders, J.E., Greinwald, J.H., Vaz, S., 2009. Aminoglycoside ototoxicity in Nicaraguan 
children: patient risk factors and mitochondrial DNA results. Otolaryngology Head and 
Neck Surgery, 140(1), pp.103-107. 
10. Tang, H.Y., Hutcheson, T., Neill, S., Drummond-Borg, M., Speer, M., 2002. Genetic 
susceptibility to aminolgycoside ototoxicity: how many are at risk? American College of 
Medical Genetics, 4(5), pp.336-339. 
11. Lu, J., Qian, Y., Li, Z., Yang, A., Zhu, Y., et al., 2010. Mitochondrial haplotypes may 
modulate the phenotypic manifestation of the deafness associated 12S rRNA 1555A>G 












12. Andrews, J.R., Shah N.S., Weissman, D., Moll, A.P., Friedland, G., et al., 2010. 
Predictors of Multidrug- and Extensively Drug-Resistant Tuberculosis in a High HIV 
Prevalence Community. Public Library of Science One,[online] Available 
at:<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012092>[Accessed 14 January 2010] 
13. Singh. H., Dulhani, N., Tiwari, P., Singh, P., Sinha, T., 2009. A prospective, 
observational cohort study to elicit adverse effects of antiretroviral agents in a remote 
resource-restricted tribal population of Chhattisgarh. Indian Journal of  Pharmacology, 
41, pp.224-226. 
14. Marra, C.M., Wechkin, H.A., Longstreth, W.T., Rees, T., Syapin, C.L., Gates, G.A., 
1997.  Hearing loss and antiretroviral therapy in patients infected with HIV-1. Archives of 
Neurology, 54(4), pp.407–410. 
15. Simdon, J., Watters, D., Bartlett, S., Connick, E., 2001. Ototoxicity associated with use of 
nucleoside analog Reverse transcriptase inhibitors: A report of 3 possible cases and 
review of the literature. Clinical Infectious Diseases, 32(11), pp.1623–1627.  
16. McNaghten, A.D., Wan, P.T., Dworkin, M.S., 2001. Correspondence: Prevalence of 
hearing loss in a cohort of HIV-infected patients. Archives of Otolaryngology Head and 
Neck Surgery, 127(12), pp.1516–1518. 
17. Carr. A., Cooper, D.A., 2000. Adverse effects of antiretroviral therapy. Lancet, 
356(9239), pp.1423–1430. 
18. Hutchin, T.P., Cortopassi, G.A., 2000. Mitochondrial defects and hearing loss. Cellular 
and Molecular Life Sciences, 57(13-14), pp.1927–1937. 
19. Prezant, T.R., Agapian, J.V., Bohlman, M.C, Bu, X., Oztaz, S., et al., 1993. 
Mitochondrial ribosomal RNA mutation associated with both antibiotic induced and non 
syndromic deafness. Nature Genetics, 4(3), pp.289-294.  
20. Bardien, S., Human, H., Hefke, G., Harris, T., Fagan, J., 2009. A rapid method  for the 
detection of five known mutations associated with aminoglycoside induced deafness. 
Biomed Central Genetics, [online] Available at: <http://www.biomedcentral.com/1471-
2350/10/2> [Accessed 30 March 2010]. 
 
21. Human, H., Hagen, Bardien, S., Hagen, C.M., de Jong, G., Harris, T., Lombard, D., 
Christiansen, M., 2010.  Investigation of Mitochondrial sequence variants associated with 
aminogloycoside-induced ototoxicity in South African TB patients on aminoglycosides. 














Part B: Literature Review 
 
Objectives of the literature review 
The objectives of the literature review were to explore studies related to aminoglycoside- 
induced ototoxicity and to review what has been published thus far in this field.   
 
Context 
With MDR-TB, aminoglycosides often have to be administered for a prolonged period of 
time and the resultant ototoxicity, is permanent.1 Different studies have reported hearing loss 
as an adverse drug reaction in patients with MDR-TB ranging from 6-40%.2,3,4 No data on the 
incidence of aminoglycoside-induced deafness has ever been documented for this country. 
 
The significant increase in MDR –TB in South Africa has been linked to the HIV epidemic.5   
Scano and Vitoria et al. recently published an article which looks at the management of HIV-
infected patients with MDR-TB and highlighted known adverse effects of antituberculous 
drugs and antiretroviral drugs which may overlap.6 
The literature is limited in that it does not address HIV positive patients on antiretroviral 
drugs when looking at ototoxicity in MDR-TB, yet frequently these drugs are given 
concomitantly. While there is insufficient evidence on the frequency and severity of 
ototoxicity from antiretroviral drugs and second-line TB drugs when given concomitantly, 
there is evidence in the literature to suggest that HIV positive patients on antiretroviral drugs 
may have an increased risk of hearing loss.7, 8  
 
Literature search strategy and quality criteria 
The information presented in this paper is supported by a Pubmed Medline search using the 
key words: aminoglycoside antibiotics, HIV, antiretrovirals, ototoxicity, tuberculosis (TB), 
multidrug resistance, sensorineural hearing loss. Clinical studies and systematic reviews 
which directly addressed aminoglycoside-ototoxicity were chosen. Several randomised 
control trials relating to aminoglycoside-induced ototoxicity were identified. Experimental 
evidence from animal studies has also been included but without expressions relating to 
randomization. The assessment of quality was based on the design of the study and the levels 
of clinical evidence. There is very little in the literature relating to antiretroviral drugs and 













Inclusion criteria for articles were studies relating to: 
 The mechanism of aminoglycoside-induced ototoxicity 
 The genetics of aminoglycoside-induced ototoxicity 
 Hearing loss in MDR-TB patients 
 Hearing loss in HIV positive individuals on antiretroviral drugs 
 Experimental animal studies where relevant (relating to ototoxicity of antiretroviral 
drugs) 
 Clinical and experimental animal studies relating to otoprotective agents in 
aminoglycoside ototoxicity 
 
Studies relating to ototoxicity of  topically administered aminoglycoside antibiotics were 
excluded as well as those studies which addressed ototoxicity in neonates and preterm 
infants. 
 
Summary and interpretation of the literature 
Mechanism of aminoglycoside ototoxicity 
Aminoglycoside antibiotics were first introduced into clinical practice in the 1940’s and 
proved to be highly effective in the treatment of multidrug-resistant TB,  or  gram-negative 
infections, such as those frequently seen in cystic fibrosis.9  The ototoxic effects of 
aminoglycosides became evident shortly thereafter, with subsequent histological studies 
revealing that administration of aminoglycosides could lead to the death of sensory hair 
cells.9   Aminoglycosides have variable cochleotoxicity and vestibulotoxicity. Streptomycin 
and gentamicin are primarily vestibulotoxic; whereas amikacin , neomycin, kanamycin are 
primarily cochleotoxic.10 Patients are generally able to physiologically compensate for 
vestibular damage, but the hearing loss is permanent, therefore cochleotoxicity is considered 
to be a more serious problem.10 
Aminoglycosides enter the inner ear fluids shortly after systemic administration. Once in the 
ear, they are taken up by the cochlear hair cells. Some studies suggest that they are taken up 
by endocytosis; others suggest that they are taken up by transduction channels.11, 12, 13 
Although they are cleared from the bloodstream within hours, they can remain sequestered 
within the cells of the inner ear for up to 6 months.14 Wang et al. demonstrated that the 












looking at ototoxicity in MDR-TB, where patients may be exposed to aminoglycosides for up 
to 18-24 months.2 
 Aminoglycosides are primarily renally excreted and in cases of renal dysfunction, serum 
levels of aminoglyoside can increase, placing a patient at risk of ototoxicity.16 When treating 
acute infections such as gram-negative sepsis, or where multiple daily doses of the 
aminoglycoside are administered, serum trough levels are monitored to prevent toxicity.17   
Peloquin et al. in a randomised trial, compared the incidences of toxicities associated with 2 
recommended dosing regimens (daily vs. three times per week of intravenous streptomycin, 
kanamycin, or amikacin) in eighty-seven patients with tuberculosis and non-tuberculous 
mycobacterial infections. The study showed that the size of the dosage and the frequency of 
administration were not associated with the incidences of ototoxicity, or nephrotoxicity 
(determined by elevated serum creatinine levels). Risk of ototoxicity (found in 37% of the 
patients) was associated with a larger cumulative dose and older age.18 
The role of mitochondria in aminoglycoside ototoxicity 
The generation of highly reactive oxygen molecules is thought to play a key role in the 
initiation of hair cell death via oxidative stress. Aminoglycoside antibiotics exert their 
antibacterial effects by interacting with the bacterial ribosome. The aminoglycosides bind to 
highly conserved sequences of bacterial 16S rRNA and thereby interfere with protein 
synthesis.19, 20 Human mitochondrial ribosomes share similarities with bacterial ribosomes, 
and therefore it is proposed that hair cell mitochondria  may be an early target of 
aminoglycosides.19,20,21 Interference with mitochondrial ribosomes could lead to the 
disruption of  the electron transport chain and the generation of free radicals resulting in 
apoptosis of cochlea hair cells.19, 20 
The A1555G mutation has been mapped to a locus within the mitochondrial ribosomal 
RNA.21 Individuals who have this mutation are predisposed to sudden hearing loss after just a 
single exposure to aminoglycosides. This mutation is also a cause of non-syndromic 
sensorineural deafness.21 The discovery of this mutation enabled scientists to understand the 
role of mitochondria in ototoxicity. 21 The A1555G mutation transforms human mitochondrial 
ribosomal RNA into a configuration that resembles ribosomal RNA of gram–negative 
bacteria, therefore carriers of this mutation are more susceptible to ototoxicity when exposed 
to aminoglycosides.21 There are 6 known mitochondrial mutations which have been linked to 
aminoglycoside-induced hearing loss: A1555G, C1494T, T1095C, 961delT+C(n), T1291C 













Genetic susceptibility: How many are at risk in the South African population? 
The increased exposure of aminoglycosides in our population raises the question: should we 
be screening for these mutations before administering aminoglycoside antibiotics? 
Having data on the prevalence of aminoglycoside use in our population is important as it 
identifies how many patients are at risk. The overall population frequency of these mutations 
also bears on the question of whether to screen for these mutations. Data from these types of 
studies will support discussion on the feasibility of genetic screening in our population. The 
Tygerberg Hospital genetics department have developed a cost effective method for the 
simultaneous detection of the six known aminoglycoside-induced mutations.22,23   This test 
facilitates the detection of susceptible individuals prior to the start of their aminoglycoside 
therapy. Knowing an individual is more susceptible to hearing loss before commencing 
aminoglycoside treatment allows for genetic counselling as well as informed consent. The 
frequency of the A1555G mutation varies quite significantly between populations (0.09%-
0.5%).24,25,26 Bardien and Human, conducted a study to determine the frequency of the six 
known mitochondrial mutations (A1555G, C1494T, T1095C, 961 delT+C(n) and A827G) in 
439 South African control samples.23 They found that the frequency of the A1555G mutation 
in the South African Black control group was 0,9% and the A827G mutation was present in 
1,1% of theAfrikaner control group.22,23  The authors concluded that the high frequency of the 
A1555G mutation is of concern given the high incidence of MDR-TB in this population 
group and additional large population studies are needed to refine its occurrence in the South 
African population.  
 
HIV, mitochondrial toxicity of antiretroviral treatment and hearing loss 
An increased incidence of hearing loss among HIV positive patients has been documented in 
a number of studies.27,28,29 There are a number of reasons that HIV positive patients are more 
at risk of hearing loss including: otitis media, opportunistic infections of the CNS, such as 
toxoplasmosis, cytomegalovirus, tuberculosis, and cryptococcosis; malignancies, including 
Kaposi's sarcoma and lymphoma, HIV-1 infection and treatment with ototoxic 
drugs.30,31,32,33,34 
There are a few reports and studies in the literature which document the ototoxicity of 
antiretroviral drugs.35,36,37,38,39,40 Five previous case reports have associated NRTIs with 
hearing loss; hearing loss was attributed to dideoxycytidine for 3 patients,35,36,37didanosine 












reported three subjects who experienced ototoxicity with combination antiretroviral treatment 
(ART). All three patients received combination antiretroviral treatment (ART) with 2–3 
nucleoside reverse transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse 
transcriptase inhibitor (NNRTI) or a protease inhibitor (PI). All 3 subjects were also over the 
age of 45, had prior hearing problems and prior exposure to occupational noise.8 Marra et al. 
in a study of 99 HIV-1-infected patients who attended an outpatient clinic in Seattle, found 
that 29% demonstrated abnormalities on screening audiometry.40 Similarly, Birchall et al. and 
Chandrasekhar et al. also reported hearing loss in a third of their patients.27,29 These 
investigators noted that the use of NRTIs within the previous 6 months was significantly 
associated with hearing loss in patients aged >35 years. Several authors attributed the hearing 
loss seen in HIV positive patients to mitochondrial DNA damage caused by the NRTIs.8,40,41 
Mitochondrial toxicity of the nucleoside analogues has already been confirmed by  in vitro 
studies .41,42 
 NRTIs act as chain terminators of mitochondrial deoxyribonucleic acid (DNA).41 The NRTIs 
are phosphorylated intracellularly to active triphosphate forms and are then incorporated into 
new DNA strands synthesized by HIV reverse transcriptase.41 Medina et al. demonstrated that 
within a few days of exposure to antiretroviral drugs, the mitochondrial DNA content of cells 
decreased.41  The medium- to long-term toxicities of NRTIs are thought to be secondary to 
the inhibition of mitochondrial DNA polymerase γ, resulting in impaired synthesis of the 
mitochondrial enzymes that generate adenosine triphosphate by oxidative phosphorylation.41 
Cortopassi  established that aging is also associated with mitochondrial DNA mutations in the 
cochlear hair cells, thereby causing hearing loss.43 Simdon postulated that if NRTIs cause 
hearing loss through mitochondrial toxicity, it is possible that they synergize with 
mitochondrial abnormalities induced by age to facilitate the development of clinically 
distinguishable hearing problems.8 This may explain why older patients who are on 
antiretroviral drugs are more at risk of hearing loss.8,27,31 
A prospective study by Schouten and Lockhart et al. reported on the audiometric findings on 
33 patients who received zidovudine (ZVD) and /or didanosine (DdI). In contrast to previous 
reports in the literature, they found no significant change in patients’ hearing after 32 weeks 
of antiretroviral treatment.44 
A recent animal study  (CBA/CaJ mice)  describe the effects of regular dosing with a 
common antiretroviral drug combination on outer hair cell (OHC) function using objective 
audiological tests, namely distortion product otoacoustic emissions (DPOAEs) and auditory 












with the nucleoside reverse transcriptase inhibitors (NRTIs), zidovudine (ZDV) and 
lamivudine (3TC), which was dissolved in their drinking water. The control subjects received 
untreated water. DPOAE levels and ABR detection thresholds were determined prior to and 
after 12 weeks of NRTI treatment. The DPOAE and ABR thresholds did not differ between 
experimental and control groups.45 
To determine whether exposure to NRTI ‘s potentiates the adverse effects of loud noise on 
OHC function, both experimental and control mice were exposed 1 week later, while still on 
the drug regimen, to a  loud noise (10-kHz octave-band noise at 105 dB SPL for 1 h). The 
mice who received NRTI’s for 12 weeks, showed significantly greater permanent reductions 
in DPOAE levels 2 weeks after the noise exposure than the untreated control animals.45 
The authors concluded that, while there was no evidence in mice for any adverse effects on 
cochlear function from NRTIs when administered alone; when combined with another 
cochlear insult such as a loud noise, NRTIs can act synergistically and adversely affect 
cochlear hair cell function.45 
One could postulate that patients on NRTIs would be more susceptible to aminoglycoside-
induced hearing loss due to possible synergistic effects (as both aminoglycosides and NRTIs 
cause damage to mitochondrial DNA). 
Prospective studies are needed to confirm whether NRTIs are associated with hearing loss 
and to identify the NRTIs most likely to induce ototoxicity and which patients are most at 
risk. 
 
Identification of gaps or needs for further research 
Development of new antituberculous drugs which are highly active, low cost and have 
reduced toxicity are needed. New protocols are needed for efficacious clinical control of TB 
patients using ordinary antimycobacterial drugs thus preventing MDR-TB and 
aminoglycoside use. Unfortunately research in this area has been very slow.  No new drugs 
except rifabutin and rifapentine have been marketed for TB (mainly in the US) during the 40 
years after release of rifampicin.46 
During the past decade, scientists have made enormous progress in understanding the 
biochemical events that lead to ototoxic hearing loss. As previously mentioned, compelling 
evidence from animal models suggests that reactive oxygen species are part of the initial 
mechanisms that trigger apoptotic and necrotic cell death in the inner ear.47 Animal studies 












animals and, more importantly, they do so without compromising drug serum levels or 
antibacterial efficacy.47 
Trials on protection from aminoglycoside ototoxicity on human subjects have only recently 
been reported. Based on the finding that salicylate afforded protection in animals, Chen and 
Huan et al. tested the efficacy of aspirin (acetyl salicylate) in a randomized double-blind 
placebo-controlled study in patients receiving gentamicin for acute infections. The authors 
demonstrated that there was a significant difference in the frequency of hearing loss between 
the placebo group and the aspirin group. Fourteen of 106 patients (13%) developed hearing 
loss in the placebo group while only 3/89 (3%) were affected in the aspirin group (p = 0.013). 
Aspirin did not influence gentamicin serum levels or the course of therapy.48 These results 
indicate that therapeutic protection from aminoglycoside ototoxicity may be extrapolated 
from animal models to the clinic. Furthermore, medications as common as aspirin can 
significantly attenuate the risk of gentamicin-induced hearing loss. Its efficacy in chronic 
aminoglycoside exposure has not been investigated in clinical studies. 
Similarly, D-methionine has been shown in animal studies (Wistar rats) to be protective 
against hearing loss caused by aminoglycoside without interfering with the antimicrobial 
efficacy of the antibiotic.49 While this drug has been shown to be very promising in animal 
studies; and is as effective in its oral form, it is not yet FDA approved. One of the problems 
of MDR-TB is the fact that aminoglycosides have to be given for prolonged periods, 
therefore further studies are need to determine whether D-methionine will be as effective in 
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Multi-drug resistant tuberculosis (MDR-TB) requiring aminoglycosides is a significant 
problem in Southern Africa with resultant increased risk of ototoxicity. 
The aims of the study were to: document the incidence of ototoxicity in MDR-TB patients 
with and without HIV, and develop clinical guidelines relating to ototoxicity in such patients. 
Design 
 Prospective cohort study 
Setting 
Brooklyn Chest Hospital in Cape Town  
Subjects 
153 HIV positive and HIV negative MDR-TB patients with normal hearing and middle ear 
status at baseline. 
Outcome Measures 
Pure tone audiometry was performed monthly for 3 months to screen for hearing loss. HIV 
status was recorded. Genetic screening was done on 115 patients using the SNaPshot 
technique to screen for six mutations in the MT-RNR1 gene: A1555G, C1494T, T1095C, 
961delT+C(n), A827G and T1291C. 
Results 
Fifty-seven percent (87/153) developed high frequency hearing loss over the 3 month period.  
Of the patients who developed hearing loss, 69% (60/87) were HIV positive and 31% were 
HIV negative. Of the 115 patients who had genetic screening, none had any known 
mutations. 
Conclusions 
Ototoxic hearing loss is common in MDR-TB patients. HIV positive patients have an 
increased risk of ototoxicity. Objective auditory monitoring should be undertaken for all 
MDR-TB patients and particularly for at risk groups, such as those that are HIV positive. 
Auditory rehabilitation for patients developing ototoxicity should be an integral part of the 
package of care of MDR-TB patients. 
 
Key Words: Aminoglycoside, ototoxicity, Multi-drug resistant TB, HIV, Audiology, MDR-














Multidrug-resistant tuberculosis (MDR-TB), defined as resistance to both isoniazid and 
rifampicin, is a growing problem globally but even more so in sub-Saharan Africa where HIV 
contributes to the burden of TB.1 The World Health Organization (WHO) reported that even 
in the absence of a nationwide survey, South Africa identified 17,615 MDR-TB isolates over 
a 4 year period.2 A survey done by Medicins Sans Frontiers showed that Cape Town 
achieved one of the best cure rates in the country with a 76% cure rate and a 82% completion 
rate in 2006.2 Despite this, MDR-TB increased twelve –fold in Khayelitsha (9 cases in 2004, 
and 109 cases in 2006).3 This increase has been linked to the HIV epidemic.3 
 
WHO guidelines dictate that, depending on susceptibility patterns, residual first-line oral 
drugs must be appropriately combined with additional second-line drugs comprising 
injectable drugs (amikacin, kanamycin, capreomycin), fluoroquinolones (ofloxacin, 
levofloxacin, moxifloxacin, gatifloxacin), old bacteriostatic second-line anti-tuberculosis 
agents (ethionamide, prothionamide, cycloserine, para-aminosalicylic acid) and anti-
tuberculosis agents with uncertain efficacy such as clofazimine, amoxicillin/clavulanate, 
clarithromycin, linezolid.4  
 
Treatment of MDR-TB is challenging even in resource rich settings. Patients have to be 
treated for at least 18-24 months with second-line TB drugs that have significant side effects 
e.g. ototoxicity and nephrotoxicity. While nephrotoxicity is reversible, otoxicity is 
permanent.5 Consequently, an increasing number of people are at risk of developing 
aminoglycoside or polypeptide related ototoxicity every year in Southern Africa, and a lack 
of audiology monitoring facilities and efficacious, cost-effective alternatives increase the risk 
of ototoxicity. 
 
In the genetics arm of this study it was determined that none of the 115 MDR-TB patients 
who had genetic screening, had any of the known six mutations which would predispose 
them to hearing loss.6,7  Eight of the patients who developed ototoxicity had the entire 
mitochondrial genome sequenced and this did not reveal any mutations in the MT-RNR1 
gene.7 
 The aims of the study were to 1) document the incidence and audiological profile of 












aminoglycoside-induced hearing loss between HIV positive and HIV negative patients with 
MDR-TB, 3)  and to develop clinical guidelines on the use of aminoglycoside antibiotics in 




The study was approved by the Committee for Human Research at Stellenbosch University 
(protocol number: N05/09/165) and the Research Ethics Committee at the University of Cape 
Town (ref:443/2005). MDR-TB patients were recruited and appropriately consented at 
Brooklyn Chest Hospital in Cape Town, South Africa. Brooklyn Chest Hospital is a 
dedicated TB hospital where patients are admitted and directly observed therapy (DOT) is 
instituted. Admission criteria are MDR-TB, extrapulmonary TB or retreatment/treatment 
failures whom due to general ill-health and/or social circumstances are unable to attend their 
local clinics for TB treatment. All patients are routinely tested for HIV after consent is taken 
and pre- and post-test counselling has been done. 
   
Inclusion criteria for the study were that patients receive aminoglycosides as part of their 
treatment within three months of hospitalisation and had normal hearing on admission.  
Serum aminoglycoside levels were not recorded. Patients underwent pure tone audiometry 
(PTA) and tympanometry on admission, then monthly for three months. Pure tone 
audiograms, including both air and bone conduction threshold measurements between 250 Hz 
and 8000 Hz, were performed in a sound treated room. The criteria for ototoxic threshold 
shift from the initial baseline audiogram were (in decibel [db]): (1) > 20  dB decrease at any 
one test frequency, (2) > 10 dB decrease at any two adjacent frequencies, or (3) loss of 
response at three consecutive frequencies where responses were previously obtained. The 
severity of hearing loss was graded (in decibel hearing level [dB HL]) as: 1) mild: PTA 
between 26-40 dB HL, moderate : PTA between 41-55 dB HL, moderately severe : PTA 
between 56-70 dB HL, severe between 71-90 dB HL and profound PTA > 90dB HL. Data 
recorded included age, gender and ethnic group and a history of noise exposure. The type of 
aminoglycoside, when it was commenced and whether patients had been on aminoglycosides 
in the previous 6 months were also recorded; as was HIV status and whether patients were on 
antiretroviral treatment. Aminoglycoside treatment is frequently commenced by local TB 
clinics several weeks prior to admission to Brooklyn Chest Hospital. Although it was not 












already been commenced on aminoglycosides, only patients with normal hearing on 
admission to the hospital were included in the study. Patients were screened for the six 
known mitochondrial mutations associated with aminoglycoside-induced hearing loss using 
the SNapShot technique.6,7 The SnapShot technique uses polymerase chain reaction (PCR) 
method to simultaneously detect the six known mutations using a single reaction. This test 
was developed by the Tygerberg genetics department.6, 7  
The t-test two sample assuming unequal variances test was used to calculate the difference in 
the mean ages between the HIV positive and HIV negative patients with hearing loss at a 
95% confidence interval. The odds ratio (at 95% confidence interval) was used to calculate 
the measure of association of HIV and aminoglycoside-induced hearing loss. The Fisher’s 
exact test was used to determine whether there were any significant associations between 
race, gender and hearing loss and whether there was a significant association between HIV 




One hundred and fifty-three MDR-TB patients were included in the study. Median age of 
patients was 36, with a range of 14 to 70 years. Sixty-six percent were female and 34% were 
male.  
All patients were on long-term treatment plans with second-line injectables (at least 6 months 
with an aminoglycoside or polypeptide or 4 months after sputum culture conversion, i.e. 2 
sputum cultures negative one month apart). Ninety-six percent had received kanamycin, 3 % 
streptomycin and 1% capreomycin. Eighty-five percent (74/87) of patients who developed 
hearing loss had acquired MDR-TB and had been on streptomycin in the preceding 6 months. 
Fifteen percent (13/87) of patients had primary MDR-TB (i.e. no previous history of TB or 
anti-tuberculosis treatment for <1 month).  
Five subjects were treated as retreatment cases initally and therefore were on streptomycin, 
but then changed to kanamycin once the sputum culture and drug susceptibility test results 
were available and confirmed MDR-TB. The two subjects on capreomycin were included in 
the study as they were on kanamycin before and were changed to capreomycin (a 
polypeptide, also with ototoxicity as side effect) towards the end of the study.     
Fifty-six percent of patients were HIV positive (86/153), 42% (65/153) were HIV negative; 2 
subjects refused HIV testing. All HIV positive patients were on highly active antiretroviral 












inhibitors (NRTI), together with a non-nucleoside reverse transcriptase inhibitor (NNRTI) or 
a protease inhibitor (PI). 
 
Eighty-seven patients (57%) developed high frequency hearing loss following admission to 
hospital. Association of hearing loss with ethnicity, gender and HIV status is summarized in 
table 1. 
HIV positive patients (60 of 87) were more likely to develop hearing loss than HIV negative 
patients (27 of 67; odds ratio 3.42, 95% confidence interval 1.66-7.09; p<0.0001). 
The mean age of the patients with HIV and sensorineural hearing loss (SNHL) was 34 years 
(standard deviation [SD] 9,1 years) and patients who were HIV negative had a mean age of 
40 years (SD13,7). There was no significant difference in the mean ages of the two groups. 
Figure 1 shows the age distribution of the HIV positive and negative patients who developed 
hearing loss.  
Of the HIV positive patients, 23% developed mild to moderate hearing loss and 46% had 
severe to profound hearing loss. Of patients who were HIV negative, 10% had mild to 
moderate hearing loss and 30% had moderate to profound hearing loss (table 2). There was 
no association between HIV status and the severity of hearing loss. 
One hundred and fifteen patients consented to genetic testing and none of these patients had 
any of the known mitochondrial mutations.6,7 Thirty-eight of the patients that developed 
hearing loss refused genetic testing therefore the presence of mutations in these patients is 
unknown. Of the patients who developed hearing loss (n=87), 49 had genetic testing and the 
hearing loss in these patients were not due to known mutations conferring genetic 
susceptibility.  
In all patients the hearing loss involved the higher frequencies (4000-8000 Hz) and in 6% this 
progressed to involve lower frequencies (500, 1000, 2000 and 3000 Hz). Fifteen percent 
(13/87) of patients developed asymmetrical hearing loss, and 13% (11/87) of patients with 




Pathophysiology of ototoxicity 
The major target for aminoglycoside ototoxicity is the sensory neuroepithelium of the inner 
ear.8 Outer hair cells of the cochlea are more susceptible than inner hair cells. Loss of 












injury is usually gradual, progressive, symmetrically bilateral and permanent.8 As in our 
study, asymmetrical losses have been reported.9 Ototoxic injury and associated hearing loss 
may progress for weeks following cessation of aminoglycoside treatment, due to the long 
half–life of aminoglycosides in cochlear tissue.10 The basal region of the cochlea is more 
susceptible to injury than the apical region, and is referred to as the ‘cochleotopic’ gradient of 
susceptibility. This cochleotopic gradient of susceptibility is expressed as high frequency 
hearing loss, which extends to include progressively lower frequencies as the cochlear 
damage becomes more extensive.11 This is consistent with our finding that hearing loss, as 
documented by pure tone audiometry, involved higher frequencies (4000 to 8000 Hz), in 57% 
of MDR-TB patients using a single parenteral second-line aminoglycoside. In all of patients 
the hearing loss involved higher frequencies and in 6% of patients this progressed to involve 
lower frequencies (500, 1000, 2000 and 3000 Hz), thus affecting speech comprehension. 
 
Diagnosis and monitoring of ototoxicity 
Ototoxicity is diagnosed by comparing the patient’s initial baseline audiogram, ideally 
obtained prior to ototoxic drug administration, to subsequent audiograms. Detecting changes 
in pure tone hearing thresholds using serial audiograms is considered a good indicator of 
ototoxic hearing loss, particularly when ultra-high frequency thresholds are included.12, 13 
Ideally, patients receiving ototoxic antibiotics should be monitored by undergoing 
audiological evaluations 1–2 times per week following initial baseline evaluation. 5, 12, 13 
Otoacoustic emissions (OAEs) are more sensitive at detecting auditory dysfunction than high 
frequency pure-tone audiometry and has also been employed to monitor ototoxicity.14 While 
57% of  this study’s participants developed hearing loss, limitations of this study are that this 
figure could be larger if a more sensitive monitoring method was used i.e. high frequency 
audiometry or OAE, and may also increase if patients are followed until after completion of 
the aminoglycoside therapy. Monitoring for hearing loss should take place for the entire 
duration of treatment. Due to the long half life of aminoglycoside in cochlear tissues, patients 
should be monitored up to about 6 months following completion of MDR therapy.15 For the 
purpose of this study pure tone audiometry was performed monthly for three months. 
However, once patients are discharged from Brooklyn Chest Hospital they are often unable to 
report back monthly to the hospital for audiometric evaluation, and because there is a paucity 
of audiological services at peripheral clinics where patients are referred to, monitoring for 













Genetic and other risk factors 
Although ototoxicity usually develops gradually, sudden profound sensorineural loss may 
follow a short duration of treatment or even a single dose of aminoglycoside. This may be 
associated with a genetic susceptibility caused by the 1555A to G substitution on the 
mitochondrial 12SrRNA.16 If genetic susceptibility to aminoglycoside-induced ototoxicity is 
suspected on the basis of family history, this can be confirmed by genetic testing. One 
hundred and fifteen patients were screened for the six known mitochondrial mutations using 
the SNapShot technique.6,7 None of these patients had the mitochondrial mutations.6,7 Further 
studies are warranted to determine whether the South African population harbors novel 
mitochondrial mutations. Other risk factors for ototoxicity include cumulative drug dose, 
duration of treatment, bacteraemia, renal or liver failure, as well as concomitant 
administration of drugs like loop diuretics which have a synergistic ototoxicity effect.17 
 
Clinical pointers to ototoxicity 
The relationship between auditory symptoms and ototoxicity with aminoglycoside antibiotics 
has not been investigated. In this study only 13% of patients with hearing loss reported 
tinnitus. It is however advisable to note any new auditory symptoms as they may be a pointer 
to ototoxicity. 
 
Incidence of ototoxicity 
Fifty-seven percent of the patients in our study developed high frequency hearing loss 
following admission to hospital. In a study which examined side effects associated with 
MDR-TB treatment, Torun et al. reported that side effects occurred in 182 of 263 patients 
(69%) and that treatment had to be modified in 55% of cases.18 Ototoxicity was the most 
common side effect and was noted in 41,8% and occurred at a mean of 4,7 +1,7 months of 
treatment. This frequent and early occurrence of ototoxicity may be due to extended exposure 
to aminoglycosides. Forty percent of these patients previously had been exposed to 
streptomycin. 18 This is similar to our study where 85% of patients had previously been 
exposed to streptomycin, and is consistent with findings of Moore et al. who showed an 
association between ototoxicity and cumulative dose of aminoglycoside.19 
 
HIV and ototoxicity 
It is estimated that 8% of new TB cases are attributable to HIV co-infection.20 None of the 












of HIV patients.17, 18 Fifty–six  percent of patients in our study were HIV positive. Our study 
showed that HIV positive patients had a four times greater risk of developing ototoxic 
hearing loss than HIV negative patients.  
 
Strategies to reduce ototoxicity 
Very little is known about the co-administration of antiretroviral drugs and second-line TB 
treatment, particularly with regard to ototoxicity. In a recent WHO report about drug 
interaction and drug toxicity among patients receiving both antiretroviral drugs and second-
line TB regimens, it was recommended that, for side effects such as peripheral neuropathy 
and psychiatric complications, the offending drug should be stopped, but only if it did not 
compromise cure.21 Some side effects like renal failure and pancreatitis are life threatening 
but also reversible on stopping the offending agent. Aminoglycoside-induced ototoxicity is 
however not reversible on stopping the drugs. There are studies where aminoglycosides were 
stopped and the treatment regimen was altered when patients developed ototoxicity, without 
compromising cure.17, 18 These studies were however conducted in HIV negative MDR-TB 
patients who were hospitalised and had side effects monitored for the entire duration of their 
treatment.17, 18 The treatment regimen should therefore be reassessed and adapted if possible 
to minimize further toxicity. There is however, a trend towards poorer outcomes and 
significant mortality in the first few months in HIV positive patients with MDR-TB.22, 23 
 Consequently, aminoglycosides are generally continued in HIV positive patients co-infected 
with MDR-TB despite the risk of developing hearing loss. 
 
Situation in South Africa 
In the Western Cape the majority of MDR-TB patients are admitted to MDR-TB hospitals 
like Brooklyn Chest Hospital. The hospital has an audiology service where patients are 
screened for hearing loss. Waiting lists for admission to the hospital are about 4-6 weeks, and 
this is likely to increase due to the increase in MDR-TB cases. In certain areas of South 
Africa, patients may wait for several months before an MDR-TB hospital bed is available.24 
Parenteral aminoglycosides are therefore commenced in the community where audiology 
screening for hearing loss generally is not done. In a recent report on audiological services in 
the Western Cape, Swart reported that the serious lack of audiological testing facilities, 
hearing aids and audiological rehabilitation is compromising MDR-TB care for patients who 














This is the 1st report that demonstrates an association between HIV and ototoxicity in MDR-
TB patients. Further study is required to elucidate the mechanism of this increased risk of 
ototoxicity in HIV positive patients. 
This study also provides alarming evidence of how commonly aminoglycoside-induced 
hearing loss occurs in MDR-TB patients, a problem that is likely to increase given the high 
prevalence of HIV in South Africa. It highlights the importance, when treating MDR-TB 
patients, of including ototoxicity as part of the informed consent process prior to commencing 
aminoglycoside therapy, of careful audiological monitoring prior to and during therapy, and 
of the need to provide hearing aids and audiological rehabilitation for patients that become 
significantly handicapped due to deafness. Due to the long waiting lists to access TB 
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Table 1 Frequency of hearing loss: total number and according to ethnic groups, gender 
and HIV status 
    Characteristic Total number in 
study (% of 
total) 
    Hearing loss (% of total in characteristic group) 
Total number of 
patients 
153 87 (57) 
      Ethnic group 
 Black 
 Coloured 
 Cape Malay 
 Caucasian 
























Exact p-value= 0.001 
* Hearing loss occurred significantly more in HIV positive compared to HIV negative












Table 2. Severity of hearing loss in HIV positive and negative subjects 
 
  HIV Status 
                            Severity of Hearing loss 
          * Mild-Moderate           ** Severe- Profound 
 
    Positive 
 
                    20 
 
                         40 
 
    Negative 
 
                     7 
 
                         20 
*Mild to moderate : PTA between 26-70 dBHL 
**Severe to profound : PTA > 71dB HL 





























Figure 1.  Graph showing age distribution of HIV positive and negative patients with 
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44 69324200 Y 
19 435031)(12 Y 
25 75053785 Y 
37 284&0780 Y 
37 28314813 N 
57 78937422 Y 
33 53 180063 Y 
22 25758483 Y 
37 28487247 Y 
70 12021143 Y 
25 58320912 Y 
51 52915287 Y 
40 24751406 Y 
22 16764375 Y 
25 29260171 Y 
27 17793951 Y 
30 84862549 N 
31 26857516 Y 
33 13605779 Y 
32 19624 139 N 
29 29150133 N 
54 23591084 y 
31 30037 121 Y 
27 298 14753 Y 

























31 56674807 Y 
39 793639~ Y 
44 571&8196 Y 
20 30054 134 Y 




Fem.le Som. lian Pos 
Female 
Male 









































Male C~oored unknown Kana 6196 
Male C~oored Neg 
Female C~oo red Neg 
Male Bli'lCk Pes 
Female C~oored Neg 
Male C~oored Neg 
Fem.le C~oored Neg 
Female C~oored Neg 
Fem.le Bli'lCk Pos 
Male C~oored Neg 
Male C~oored Neg 
Male :ape Mala) Neg 
Male C~oo red Neg 
Male Bli'lCk Neg 
Female Bli'lCk Pes 
Fem.le :.pe M.I.) Neg 
Female Bli'lCk Pes 
Fem.le Bli'lCk Pes 
Female Bli'lCk Pes 
Female Bli'lCk Pes 
Female Bli'lCk Neg 
Male Caucas ian Neg 
M.le Bli'lCk Neg 
Male Bli'lCk Neg 

















Fem.le Coloored Pos 
Male C~oored Neg 
Male Coloo red Neg 
Female C~oo red Neg 




Ka na &8.2 








Ka na 68.62 
Kana 6S 63 
Kan. 68.75 














































































































Sym Mild N 
N 
Sym Profoond N 





Sym Mild N 
Sym Modera1e Y 




Sym Severe N 
N 
N 
Sym Severe N 
Sym Mild Y 




























































































































































































































































































































































































Female Coloored Pos 
Female Coloored Neg 
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Female 8111Ck Neg 
Female C~oured Pos 
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: Dr B Palel Enquiries 
Telephone 
Fu 
: (021) 404-4256 
; (021) 4044304 
E~mail bpalel@pgwc.gov.za 
Reference : Resem:h 
Dale II October 2006 
Dr Zubair Doolarkhan & Co-investigators 
Dear Dr Doolarkhan 
RESEARCH: OTOTOXICITY STUDY 
Your recent letter to the hospital refers. 
Departement van Gesondheid 
Department of Health 
lSebe lezeMl)ilo 
You are hereby granted permission to proceed with your research . 
Please note the following:-
a) Your research may not interfere with normal patient care. 
b) Hospital staff may not be asked to assist in the research. 
c) No hospital consumables and stationery may be used. 
d) Please introduce yourself to the person in charge of an area before commencing. 
I would like to wish you every success with your project. 
Yours truly 
DR B PATEL 
For CHIEF EXECUTIVE OFFICER 
BP/em 11/10/06 
Groote Schuur H()ypit(l/ 
Private Bag, 
Obyervalory. 7935 











UNIVERSITY OF CAPE TOWN , 
05 June 2007 
REC REF: 443/2005 
Dr Z Doolarkhan 
Dept of Orthorhinolaryngology 
GSH 
Dear Dr Doolarkhan 
Health Sciences Faculty 
Research Ethics Committee 
Room ES2-24 Groote Scbuur Hospital Old Main Building 
Observatory 7925 
Telephone r021 14()() ()]3K • Fac,imile ~)2114()6 6411 
e-mail: prea~:HC.J@(Um·.ucl .. ac.2:a 
PROJECT TITLE: GENETICS OF AMINOGLYCOSIDE OTOTOXICITY 
Thank you for submitting your srudy to the Research Ethics Committee for review. 
I have pleasure in informing you that the Ethics Committee has formally approved the above mentioned 
srudy. We also note the approval letters from Brooklyn Chest, Groote Schuur and New Somerset Hospitals. 
Please ensure that you comply with requirements specified by the respective hospitals. 
This serves to confirm that the University of Cape Town Research Ethics Committee complies to the Ethics 
Standards for Clinical Research with a new drug in patients, based on the Medical Research Council (MRC-
SA), Food and Drug Administration (FDA-USA), International Convention on Harmonisation Good Clinical 
Practice (ICH GCP) and Declaration of Helsinki guidelines. 
The Research Ethics Committee granting rbis approval is in compliance with the ICH Harmonised Tripartite 
Guidelines E6: Note for Guidance on Good Clinical Practice (CPMP /ICH/135/95) and FDA Code Federal 
Regulation Part 50, 56 and 312. 
Please note that the ongoing ethical conduct of the srudy remains the responsibility of the principal 
investigator. 
Please quote the REC. REF in all your correspondence. 
Yours sincerely 
PROF M BLOCKMAN 












19 JWle 2008 
DrS Bardten 
\J NIV E R51TEIT -~ TEll fNBOSCH -UNIVERSITY 
Jou ~t nl\\lfnn, 01 _ )" II' knowltdqr parlnu 
Division of Molecular Biology and Human GcncliCS 
Dept of Biomedical Science 
Dear Dr Bardien 
RESEARCH PROJECT: "AN INVESTIGATION OF TnE ROLE PATHOGENIC AND 
DISEASE PREDISPOSING G ENETIC FACTORS IX 
l\1ITOCHONDKJAL DNA IN DIFFERENT FORMS OF HEARING 
IMPA[Rl\IENT" 
PROJECT NUl\tBER NOS/09/165 
At a meetmg of the Committee for Human Research that was held on 11 June 2008 the progress repan 
for the abovementioned proJcct has been approved and the study has been granted an extenSion for a 
perkMi of oa~ year from tbis dlle. 
ReoewII nile: II June 2008 Expiry Da le: 11 June 2009 
Please remember to submit progress reports in goodtime for annual renewal m the standard CHR fonnat. 





RESE~ EVELOPME!\T AND SUPPORT (TYG[RBERG) 
9207 I E·mall: mertrude@sun.ac.za 
. 0 ~z._ 
, P' 
v •• " •• ' . ' 0 ......... G .. . ....... c .............. 0' . . ..... .... h. 
A'<I.lIn. "' ...... lnl •• ntwl .... I1 .............. 1I ..... M"1:h O ..... loprn.n ...... S.,,...... OI.I,lon 
~ Ie,. '_J . T" • ..-. nos - Suo<l-Af..,1<&ISoo.th AInu 
To!· -27 Jt 'll "17 - hblfu: *271 1 'JI HH 












17 February 2010 MAILED 
Dr S Bardien 
Dep Biomedical Sciences 
Molecular Biology and Human Genetics 
Doar Dr Sardien 
" An investigation of the role of pathogeni and disease predisposing genetic factors in mitochondrial DNA in 
different forms of hearing impairment .. 
ETHICS REFERENCE NO: N05/09/1 65 
RE : AMENDMENT 
Your letter dated 11 February 2010 refers. 
Committee approved the amended documentation In accordance With the The Chairperson of the Health Research Eth 
authonty given to him by the Committee. I 




MRS EL ROHLAND 
RESEARCH DEVELOPMENT AND SUPP T 
Tel: 021 938 9677 I E-mail : elr@sun.ac.za 
Fax: 021 931 3352 
17 February 2010 14:36 
Verbind Optlmale Gesondheid . Committed to Optimal Health 
Afd.llng Navoralngso -ateun . Olvlslon of Research Development and Support 
POSbuS
T I 
.' Box 19063 · Tygerberg 7505 · Suid-AfrikalSouth Africa 
.2721938 9075 , FaksIFax: .27219313352 











To: Dr Lyn Hom 
Hea1th Research Ethics Commi ee 
Faculty of Hea1th Sciences 
Stellenbosch University 
Dear Dr Hom 
II February 20 I 0 
re: amendment to project: An ~ vestigation of the role of pathogenic and disease 
predisposing genetic factors mitocbondrial DNA in different forms of bearing 
impairment. Ref no. N05/091 65 
Your letter dated 8 February I fers. My apologies if it was not clear in my letter dated 3 
February 2010 that the HIV-st tus of patients only (the cases) and not controls has been 
recorded. 
The purpose of my letter was 
and use the infonnation on th 
drug-induced hearing loss. 
As requested, please find the 
Yours sincerely 
... ~~~ 
Dr. Soraya Bardien 
University of Stellenbosch 
determine whether we can make this amendment to the study 
HIV-status to see ifit is one of the factors that may impact on 
atient Infonned consent fonn ' attached. 
Molecular Biology and Hum Genetics 
Fourth Floor, Fisan Building I 
Faculty of Health Sciences 











PARTICIPANT INFORMATION AND INFORMED CONSENT FORM 
TITLE OF RESEARCH PROJECT: 
An investigation of the role of pathogenic and disease predisposing genetic factors in 
mitochondrial DNA in different forms of hearing impairment. 
ETHICS REFERENCE NUMBER: N05/09/165 (US) 
INVESTIGATORS: Dr Soraya Bardien \ Prof Greetje de Jong 1, Prof Simon Schaaf\ Mrs 
Debbie Lombard', Dr Tashneem Harris2, Prof Johan Fagan2, Ms Lucretia Petersen2, Ms 
Sadika Parker1&2 
ADDRESSES: 
1 University of Steilenbosch, Tygerberg, 
2 University of Cape Townl Groote Schuur Hospital, Observatory. 
CONTACT NUMBERS: Tel: Prof Greetje de Jong 021·9384217 
Tel: Mrs Debbie Lombard 082 428 8693 
Dear study participant 
We would like to invite you to participate in a research study that involves DNA (genetic) 
analysis and possible long-term storage of blood or tissue specimens. 
• Please take some time to read the information presented here which will explain 
the details of this project. 
• Ask the study staff or doctor any questions about any part of this project that you 
do not fully understand. It is very important that you are fully satisfied that you 
clearly understand what this research entails and how you could be involved. 
• Also, your participation is entirely voluntary and you are free to decline to 
participate. If you say no, this will not affect you negatively in any way 
whatsoever. 
• You are also free to withdraw from the study at any point, even if you do agree 
to take part initially. 
This research study has been approved by the ethics Committees for Human 
Research at Stellenbosch University and at the University of Cape Town and it will 
be conducted according to international and locally accepted ethical guidelines for 
research, namely the Declaration of Helsinki and the South African Medical Research 
Council's (MRC) Guidelines on Ethics for Medical and Genetic Research. 
What is DNA analysis or genetic research? 
Genetic material, also called DNA, is usually obtained from a small blood sample. 
Occasionally other tissues may be used. DNA consists of numerous genes, strung 
together in long strands and found in every cell in the human body. Genes are the 
"blueprint" that determines what we look like and sometimes what kind of diseases we 
may be susceptible to. Worldwide research in this field is continuously discovering new 
information that may be of great benefit to future generations and also that may benefit 
people today, who suffer from particular diseases or conditions. 
What is this research study all about? 
In most of your cells there are tiny structures called mitochondria that are responsible 
for producing energy needed for various processes in the eell. It has been shown that 
defects in the genes in the mitochondria can cause hearing loss. Either these defects 
result in hearing loss on their own or sometimes they need other factors such as certain 
types of antibiotics to result in hearing loss. This research project will investigate 










whether defects in mitochondrial genes account for a significant proportion of individuals 
with hearing loss in the South African population. 
Why have you been invited to participate? 
We would like to establish whether the genes in your mitochondria contain any defects 
that has resulted in hearing impairment or may predispose you! your child to hearing 
loss when certain antibiotics are taken. 
What procedures will be involved? 
We will need to take a small sample of blood (10-20 ml which is equivalent to 2-4 
teaspoons) from one of your veins, usually in the arm. We will also need to test your 
hearing using a standard procedure. 
Are there any risks involved in genetic research? 
You may experience minor pain and!or bruising at the site where blood is taken. 
Some insurance companies may mistakenly assume that taking part in genetic research 
indicates a higher risk for disease. Thus no information about you or your family will be 
shared with such companies. 
Are there benefits to taking part in this study & will you get told your results? 
This research project is important as it may reveal some of the genetic factors involved 
in hearing impairment in South African populations. The results from this study may 
have important implications for your family members. Your personal results will be made 
known to your clinician only if they indicate that you may have a genetic predisposition 
for developing hearing loss and therefore may need genetic counseling by a trained 
genetic counselor. 
How long and where will your blood be stored? 
Your blood and DNA will be stored for about 5-10 years in the Division of Medical 
Biochemistry at the University of Stellenbosch, Faculty of Health Sciences. 
Is there a chance that it will be used for other research? 
Your blood will only be used for genetic research that is directly related to 
studies on hearing impairment. Also if the researchers wish to use your stored blood for 
additional research in this field they will be required to apply for permission to do so 
from the Human Research Ethics Committees at Stellenbosch University and the 
University of Cape Town. 
If you do not wish your blood specimen to be stored after this research study is 
completed you will have an opportunity to request that it be discarded when you sign 
the consent form. 
How will your confidentiality be protected? 
Your identity will be kept confidential and the research staff will use a numbered code 
for your DNA sample. Access to your personal information will be limited to authorised 
scientists and clinicians only. Any scientific publications, lectures or reports resulting 
from the study will not identify you by name. 
Will you or the researchers benefit financially from this research? 
You will not be paid to take part in this study and the researchers will not benefit 
financially by conducting this research. 
In the unlikely event that the research leads to the development of a commercial 
application or patent, you or your family will not receive any profits or royalties. 
However profits will be reinvested to supporting the cause of further research, which 
may bring benefits to your family or community in the future. 
Thank you for taking part in this research project! 










Signed at (place ) ............ ......... .................... .... ..... on (date) ..... .... ..... .. ............ .. .. . 
Signature of participant! legal guardian Signature of witness 
Declaration by investigator 
I (name) ............... .. ......... .... ...... .. . .. .................. . ......... .. .. .. .. .. .... declare that: 
• I explained the infonnation in this documentto .......... .... . ........ ............... .. . 
• I encouraged himlher to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research as 
discussed above. 
• I did/did not use a translator. (If a translator is used then the translator must sign 
the declaration below. 
Signed at (place) .......... .. ........ ....... ..... .. .. ............. . on (date) ..... .. ... ............... .. ... .. 
Signature of investigator Signature of witness 
Declaration By Translator 
I (name) ........ . .. ............. ...... ...... .. ... . .. ............. ...... ......... ... .. ..... declare that: 
• I assisted the investigator (name) .. ................... ... ... .. ......................... . 
to explain the infonnation in this document to (name of participant) 
...... ............... ......... ............... .. . ........... ...... ... .. ... ... .. using the 
language medium of AfrikaanslXhosa. 
• We encouraged himlher to ask questions and took adequate time to answer them. 










Patient consent furm 
PARTICIPANT INFORMATION AND INFORMED CONSENT 
FORM FOR RESEARCH INVOLVING GENETIC STUDIES 
TITLE OF RESEARCH PROJECT: 
I Genetics of Aminoglycoside Ototoxicity. 
Reference Number: 44312005 
Principal Investigators: Dr Tasbneem Harris; Lucretia Petersen; Dr Soraya Bardien 
Address: Department of Otolaryngology, H53 old main building, Groote Scbuur 
Hospital,Observatory, 7925 
Contact Number: 021 406 6420 
Dear study participant! legal guardian of the study participant (delete where not applicable) 
We would like to invite you! your child to participate in a research study that involves DNA 
(genetic) analysis and possible long-term storage of blood or tissue specimens . 
• :. Please take some time to read the information presented here which will explain the 
details of this project. 
.:. Please ask the study staff or doctor any questions about any part of this project that 
you do not fully understand. It is very important that you are fully satisfied that you 
clearly understand what this research entails and how you could be involved . 
• :. Also, your! your child's participation is entirely voluntary and you are free to 
decline to participate. If you say no, this will not affect you! your child negatively in 
any way whatsoever . 
• :. You! your child are also free to witbdraw from tbe study at any point, even if you 
do agree to take part initially. 
This research study has been approved by the Faculty of Healtb Sciences Researcb Ethics 
Committee oftbe University of Cape Town. 
Wbat is DNA analysis or genetic researcb? 
Genetic material, also called DNA, is usually obtained from a small blood sample. 
Occasionally other tissues may be used. DNA consislS of numerous genes, strung together in 
long strands and found in every cell in the human body. Genes are the "blueprint" that 
determines what we look like and sometimes what kind of diseases we may be susceptible to . 
Worldwide research in this field is continuously discovering new infurmation that may be of 
great benefit to future generations and also that may benefit people today, who sutler from 










What does this particular research study involve? 
In most of your cells there are tiny structures called mitochondria that are responsible for 
producing energy needed for various processes in the cell. It has been shown that defects in 
the genes in the mitochondria can cause hearing loss. Either these defects result in hearing 
loss on their own or sometimes they need other factors such as certain types of antibiotics to 
result in hearing loss. This research project will investigate whether defects in mitochondrial 
genes account for a significant proportion of individuals with hearing loss in the South 
African popUlation. 
Why have you or your child been invited to participate! 
We would like to establish whether the genes in yourl your child's mitochondria contain any 
defects that have resulted in hearing impairment or may predispose youl your child to 
hearing loss when certain antibiotics are taken. 
What procedures wiD be involved in this research? 
We will need to take a small sample of blood (10-20 mI which is equivalent to 2-4 
teaspoons) from one of your / your child's veins, usually in the arm. We may also need to 
test your I your child's hearing using a standard procedure. 
Are there any risks involved in genetic research? 
Youl your child may experience minor pain and/or bruising at the site where blood is taken. 
Some insurance companies may mistakenly assume that taking part in genetic research 
indicates a higher risk for disease. Thus no information about you or your family will be 
shared with such companies. 
Are there any benefits to your taking part in tbis study and will you get told your 
results? 
This research project is important as it may reveal some of the genetic factors involved in 
hearing impairment in South African populations. The results from this study may have 
important implications for your family members. Yourl your child's personal results will be 
made known to your clinician only if they indicate that you! your child may have a genetic 
predisposition for developing hearing loss and therefure may need genetic counseling by a 
trained genetic counselor. 
How long wiD your/ your cbild's blood be stored and where will it be stored? 
Your/ your child's blood and DNA will be stored for about 5-10 years in the Division of 
Medical Biochemislly at the University ofStellenbosch, Faculty of Health Sciences. 
If your or your cbild's blood is to be stored is there a chance that it will be used for 
other research? 
Yourl your child's blood will only be used fur genetic research that is directly related to 
studies on hearing impairment Also if the researchers wish to use yourl your child's stored 
blood fur additional research in this field they will be required to apply fur permission to 










If you do not wish your/ your child's blood specimen to be stored after this research study is 
completed you will have an opportunity to request that it be discarded when you sign the 
consent form. 
How wiD your confidentiality be protected! 
Your/ your child's identity will be kept confidential and the research staff will use a 
numbered code for your DNA sample. Access to your personal information will be limited to 
authorised scientists and clinicians only. Any scientific publications, lectures or reports 
resulting from the study will not identify you by name. 
Will you or the researchers benefit financially from this research? 
You/ your child will not be paid to take part in this study and the researchers will not benefit 
financially by conducting this research. 
In the unlikely event that the research leads to the development of a commercial application 
or patent you or your family will not receive any profits or royalties. However profits will be 
reinvested to supporting the cause of further research, which may bring benefits to your 
family or commWlity in the future. 
Thank you for taking part in this research project! 
Declaration by participant or legal guardian (in the case of a minor) 
By signing below, I ......................................... ... ............................ ... ........ . 
agree! or give permission for my child to take part in a genetic research study entitled" An 
investigation of the role of pathogenic and disease predisposing genetic factors in 
mitochondrial DNA in different forms of hearing impairment" 
I declare that: o I have read or had read to me this information and consent form and it is written 
in a language with which I am fluent and comfortable. 
o I have had a chance to ask questions and all my questions have been adequately 
answered. 
o I understand that taking part in this study is voluntary and I / my child have not 
been pressurised to take part. 
(Please tick the option you choose below o I agree that my I my child's blood or tissue sample can be stored, but I can 
choose to request at any time that my stored sample he destroyed. I have the 
right to receive confirmation that my request has been carried out. 
OR 
o Please destroy my I my child's blood sample as soon as the current research 
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